CGRP receptor antagonists: an expanding drug class for acute migraine?

Bibliography

• Stewart WF, Simon D, Shechter A, Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol 1995;48(2):269-80
   PubMed Web of Science ®Google Scholar
• Graham J, Wolff H. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39:737-63
   Google Scholar
• Parsons AA, Strijbos PJ. The neuronal versus vascular hypothesis of migraine and cortical spreading depression. Curr Opin Pharmacol 2003;3:73-7
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995;15:277-80
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Charbit AR, Andreou AP, Neurobiology of migraine. Neuroscience 2009;161:327-41
   PubMed Web of Science ®Google Scholar
• McCulloch J, Uddman R, Kingman TA, Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986;83:5731-5
   PubMed Web of Science ®Google Scholar
• O'Connor TP, Van der Kooy D. Pattern of intracranial and extracranial projections of trigeminal ganglion cells. J Neurosci 1986;6:2200-7
   PubMed Web of Science ®Google Scholar
• Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache. CNS Drugs 2001;15:745-53
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Messlinger K, Pawlak M, Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 1995;114:1397-02
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Mulder H, Goadsby PJ, Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin generelated peptide. J Auton Nerv Syst 1998;70:15-22
   PubMedGoogle Scholar
• Kristiansen KA, Edvinsson L. Neurogenic inflammation: a study of rat trigeminal ganglion. J Headache Pain 2010;11:485-95
   PubMed Web of Science ®Google Scholar
• Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004;24:611-22
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev 2005;48:438-56
   PubMed Web of Science ®Google Scholar
• Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996;16:310-16
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Ekman R, Jansen I, Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 1987;7:720-8
   PubMed Web of Science ®Google Scholar
• Lassen LH, Jacobsen VB, Haderslev PA, Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain 2008;9:151-7
   PubMed Web of Science ®Google Scholar
• Gray DW, Marshall I. Nitric oxide synthesis inhibitors attenuate calcitonin gene-related peptide endothelium-dependent vasorelaxation in rat aorta. Eur J Pharacol 1992;212:37-42
   Web of Science ®Google Scholar
• Raddino R, Pela G, Manca C, Mechanism of action of human calcitonin generelated peptide in rabbit heart and in human mammary arteries. J Cardiovasc Pharmacol 1997;29:463-70
   PubMed Web of Science ®Google Scholar
• Li J, Vause CV, Durham PL. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 2008;1196:22-32
   PubMed Web of Science ®Google Scholar
• Wei EP, Moskowitz MA, Boccalini P, Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 1992;70:1313-19
   PubMed Web of Science ®Google Scholar
• Grant AD, Pinter E, Salmon AM, Brain SD. An examination of neurogenic mechanisms involved in mustard oil-induced inflammation in the mouse. Eur J Pharmacol 2005;507(1-3):273-80
   PubMed Web of Science ®Google Scholar
• Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996;17:533-85
   PubMed Web of Science ®Google Scholar
• van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997(5):649-78
   PubMed Web of Science ®Google Scholar
• Christopoulos G, Paxinos G, Huang XF, Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 1995;73:1037-41
   PubMed Web of Science ®Google Scholar
• Tsai SH, Tew JM, McLean JH, Cerebral arterial innervation by nerve fibers containing calcitonin gene-related peptide (CGRP): I. Distribution and origin of CGRP perivascular innervation in the rat. J Comp Neurol 1988;271:435-44
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CA, Calamari A, Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010;169:683-96
   PubMed Web of Science ®Google Scholar
• Uddman R, Edvinsson L, Ekman R, Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-6
   PubMed Web of Science ®Google Scholar
• Jansen I, Uddman R, Hocherman M, Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol 1986;20:496-501
   PubMed Web of Science ®Google Scholar
• Jansen I, Uddman R, Ekman R, Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin generelated peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides 1992;13:527-36
   PubMed Web of Science ®Google Scholar
• Gupta S, Amrutkar DV, Mataji A, Evidence for CGRP re-uptake in rat dura mater encephali. Br J Pharmacol 2010;161:1885-98
   PubMed Web of Science ®Google Scholar
• Arulmani U, Maassenvandenbrink A, Villalon CM, Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004;500:315-30
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
   PubMed Web of Science ®Google Scholar
• Gallai V, Sarchielli P, Floridi A, Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-90
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Modos EA, NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003;106:461-70
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, Alessandri M, Figini M, Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995;60:119-23
   PubMed Web of Science ®Google Scholar
• Cady RK, Vause CV, Ho TW, Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49:1258-66
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania— evidence for trigemino-parasympathetic activation. Cephalalgia 1996;16:448-50
   PubMed Web of Science ®Google Scholar
• Ashina M, Bendtsen L, Jensen R, Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology 2000;55:1335-40
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010;30:1179-86
   PubMed Web of Science ®Google Scholar
• Hansen JM, Thomsen LL, Olesen J, Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. Headache 2011;51:544-53
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, Lipka K, Ashina M, No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 2005;58:561-8
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002;346:257-70
   PubMed Web of Science ®Google Scholar
• Longmore J, Shaw D, Smith D, Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigeminocerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997;17:833-42
   PubMed Web of Science ®Google Scholar
• Potrebic S, Ahn AH, Skinner K, Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003;23:10988-97
   PubMed Web of Science ®Google Scholar
• Ashgar MS, Hansen AE, Kapijimpanga T, Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in healthy volunteers. Neurology 2010;75:1520-6
   PubMed Web of Science ®Google Scholar
• Villalon CM, Centurion D, Valdivia LF, An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 2002;45:199-210
   PubMedGoogle Scholar
• Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53:167-8
   PubMed Web of Science ®Google Scholar
• Summ O, Andreou AP, Akerman S, A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain 2010;11:477-83
   PubMed Web of Science ®Google Scholar
• Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-88
   PubMed Web of Science ®Google Scholar
• Diener HC, Katsarava Z. Medication overuse headache. Curr Med Res Opin 2001;17:S17-21
   PubMedGoogle Scholar
• Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 2011;12:593-60
   PubMed Web of Science ®Google Scholar
• Meng ID, Dodick D, Ossipov MH, Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia 2011;31:851-60
   PubMed Web of Science ®Google Scholar
• Visser WH, Jaspers NM, de Vriend RH, Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996;16:554-9
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V, Consensus statement: cardiovascular safety profile of triptans (5- HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-25
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Post-triptan era for the treatment of acute migraine. Curr Pain Headache Rep 2004;8:393-8
   PubMedGoogle Scholar
• Durham PL. CGRP receptor antagonist: a new choice for acute treatment of migraine? Curr Opin Investig Drugs 2004;5:731-5
   PubMedGoogle Scholar
• Geppetti P, Capone JG, Trevisani M, CGRP and migraine: neurogenic inflammation revisited. J Headache Pain 2005;6:61-70
   PubMedGoogle Scholar
• Goadsby PJ. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 2005;65:2557-67
   PubMed Web of Science ®Google Scholar
• Iovino M, Feifel U, Yong CL, Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645-56
   PubMed Web of Science ®Google Scholar
• Williams TM, Stump CA, Nguyen DN, Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett 2006;16:2595-8
   PubMed Web of Science ®Google Scholar
• Bell IM, Bednar RA, Fay JF, Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett 2006;16:6165-9
   PubMed Web of Science ®Google Scholar
• Burgey CS, Stump CA, Nguyen DN, Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine. Bioorg Med Chem Lett 2006;16:5052-6
   PubMed Web of Science ®Google Scholar
• Shaw AW, Paone DV, Nguyen DN, Caprolactams as potent CGRP receptor antagonists for the treatment of migraine. Bioorg Med Chem Lett 2007;17:4795-8
   PubMed Web of Science ®Google Scholar
• ter Haar E, Koth CM, Abdul-Manan N, Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 2010;18:1083-93
   PubMed Web of Science ®Google Scholar
• Paone DV, Shaw AW, Nguyen DN, Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-7
   PubMed Web of Science ®Google Scholar
• Bell IM, Gallicchio SN, Wood MR, Discovery of MK-3207: a highly potent, orally bioavailable CGRP receptor antagonist. ACS Med Chem Lett 2010;1:24-9
   PubMed Web of Science ®Google Scholar
• Paone DV, Nguyen DN, Shaw AW, Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918. Bioorg Med Chem Lett 2011;21:2683-6
   PubMed Web of Science ®Google Scholar
• Fraser NJ, Wise A, Brown J, The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 1999;55:1054-9
   PubMed Web of Science ®Google Scholar
• Hilairet S, Belanger C, Bertrand J, Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol Chem 2001;276:42182-90
   PubMed Web of Science ®Google Scholar
• Kamitani S, Sakata T. Glycosylation of human CRLR at Asn123 is required for ligand binding and signaling. Biochim Biophys Acta 2001;1539:131-9
   PubMed Web of Science ®Google Scholar
• Kuwasako K, Kitamura K, Nagoshi Y, Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J Biol Chem 2003;278:22623-30
   PubMed Web of Science ®Google Scholar
• Ittner LM, Koller D, Muff R, The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 2005;44:5749-54
   PubMed Web of Science ®Google Scholar
• Koller D, Born W, Leuthauser K, 15. The extreme N-terminus of the calcitonin-like receptor contributes to the selective interaction with adrenomedullin or calcitonin gene-related peptide. FEBS Lett 2002;531:464-8
   PubMed Web of Science ®Google Scholar
• Hay DL, Christopoulos G, Christopoulos A, Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-lpiperazinyl] carbonyl]pentyl]amino]-1- [(3,5-dibromo-4-hydroxyphenyl)methyl]- 2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2 H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors–the role of receptor activity modifying protein 1. Mol Pharmacol 2006;70:1984-91
   PubMed Web of Science ®Google Scholar
• Mallee JJ, Salvatore CA, LeBourdelles B, Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002;277:14294-8
   PubMed Web of Science ®Google Scholar
• Salvatore CA, Mallee JJ, Bell IM, Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006;45:1881-7
   PubMed Web of Science ®Google Scholar
• Salvatore CA, Hershey JC, Corcoran HA, Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416-21
   PubMed Web of Science ®Google Scholar
• Salvatore CA, Moore EL, Calamari A, Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. Pharmacol Exp Ther 2010;333:152-60
   PubMed Web of Science ®Google Scholar
• Troltzsch M, Denekas T, Messlinger K. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 2007;562:103-10
   PubMed Web of Science ®Google Scholar
• Kapoor K, Arulmani U, Heiligers JP, Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol 2003;140:329-38
   PubMed Web of Science ®Google Scholar
• Kapoor K, Arulmani U, Heiligers JP, Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur J Pharmacol 2003;475:69-77
   PubMed Web of Science ®Google Scholar
• Moreno MJ, Abounader R, Hebert E, Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002;42:568-76
   PubMed Web of Science ®Google Scholar
• Arulmani U, Schuijt MP, Heiligers JP, Effects of the CGRP receptor antagonist BIBN4096BS on CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol 2004;94:291-7
   PubMed Web of Science ®Google Scholar
• Wu DM, van Zwieten PA, Doods HN. Effects of calcitonin gene-related peptide and BIBN4096BS on myocardial ischemia in anesthetized rats. Acta Pharmacol Sin 2001;22:588-94
   PubMed Web of Science ®Google Scholar
• Petersen KA, Birk S, Doods H, Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004;143:697-704
   PubMed Web of Science ®Google Scholar
• Petersen KA, Birk S, Lassen LH, The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005;25:139-47
   PubMed Web of Science ®Google Scholar
• Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005;25:5877-83
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, BIBN 4096 BS Clinical Proof of Concept Study Group. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10
   PubMed Web of Science ®Google Scholar
• Farinelli I, De Filippis S, Coloprisco G, Future drugs for migraine. Intern Emerg Med 2009;4(5):367-73
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-12
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Martin V, Lipton RB, Randomized controlled study of telcagepant plus Ibuprofen or acetaminophen in migraine. Headache 2011;51:533-43
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlof CG, Silberstein SD, Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010;30:1443-57
   PubMed Web of Science ®Google Scholar
• Connor KM, Aurora SK, Loeys T, Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 2011;51:73-84
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73:970-7
   PubMed Web of Science ®Google Scholar
• Ho TW, Ho AP, Chaitman BR, Randomized, controlled study of telcagepant in patients with migraine and Coronary Artery disease. Headache 2012; published online Jan 6 2012; doi: 10.1111/j.1526-4610.2011.02052.x
   Google Scholar
• van der Schueren BJ, Blanchard R, Murphy MG, The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol 2011;71:708-17
   PubMed Web of Science ®Google Scholar
• Available from: http://www.merck.com/newsroom/news-release-archive/financial/2011_0729.html
   Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011;31:712-22
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlof C, BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011;31:573-84
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache 2011;51(1):118-23
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. J Headache Pain 2011;12:275-80
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia 2011;31(6):748-50
   PubMed Web of Science ®Google Scholar